In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

J&J buys Cougar Biotechnology for about $894mm

Executive Summary

Fresh from initiating the battle to win global rights to Remicade from former marketing partner Schering-Plough, which is in the process of being acquired by Merck, Johnson & Johnson has acquired Cougar Biotechnology (cancer therapeutics) for $43 per share (a 24% premium), or a total of about $894mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Full Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register